Devices › Implantable cardioverter defibrillator (non-crt)
Device brand name · Implantable cardioverter defibrillator non-crt
Visia AF MRI S VR SureScan: medical device reports filed with FDA
297 reports name it, 2019–2026. Manufacturer given most often on reports: Medtronic Europe Sarl. Product code LWS.
- 297
- device reports naming the brand
- 0% of all MAUDE reports · about 41 a year
- 34
- reports, 12 months to August 2026
- 37 in the 12 months before
- 26.9%
- classified as malfunction
- 37.4% across the product code
- 1.3%
- classified as death, as reported
- 4 reports · not verified by FDA
297 medical device reports received by FDA name the brand "Visia AF MRI S VR SureScan" (implantable cardioverter defibrillator non-crt); the manufacturer given most often on reports is Medtronic Europe Sarl; received from May 2019 to August 2026. Brand names are as the reporter or manufacturer wrote them, so one product can appear under several spellings.
34 reports arrived in the 12 months to August 2026, close to the 37 of the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are injury (71.7%), malfunction (26.9%) and death (1.3%); across all implantable cardioverter defibrillator (non-crt) reports (product code LWS) death is recorded in 2.7% and malfunction in 37.4%. Event type is the reporter's classification of the report, not a verified outcome.
The device problems coded most often are device sensing problem (34%), inappropriate/inadequate shock/stimulation (24.2%) and premature discharge of battery (11.8%). The patient problems coded most often are shock from patient lead(s), tachycardia and bacterial infection. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Reports by month, five years
Reports by the month FDA received them. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
By year received
Event type and report source
Event type, as classified on the report
Who filed the report
Grey bar: all 380,959 reports carrying product code LWS. Event type is the filer's classification and is not verified by FDA.
Device problems coded
| Device problem (FDA code) | Reports | Share | Share across product code |
|---|---|---|---|
| Device sensing problem | 101 | 34% | 3.9% |
| Inappropriate/inadequate shock/stimulation | 72 | 24.2% | 12.8% |
| Premature discharge of battery | 35 | 11.8% | 8.1% |
| Pacing problem | 32 | 10.8% | 3.8% |
| Signal artifact/noise | 31 | 10.4% | 8% |
| Electromagnetic interference | 26 | 8.8% | 0.6% |
| Over-sensing | 25 | 8.4% | 21.1% |
| Mechanical problema mechanical problem | 20 | 6.7% | 1% |
| Failure to deliver shock/stimulation | 14 | 4.7% | 0.3% |
| Electrical /electronic property probleman electrical or electronic problem | 11 | 3.7% | 0.8% |
| Battery problema problem with the battery | 8 | 2.7% | 2% |
| Failure to interrogate | 7 | 2.4% | 0.9% |
| High impedance | 7 | 2.4% | 15.6% |
| Impedance problem | 4 | 1.3% | 4.4% |
| Misconnection | 4 | 1.3% | 0.1% |
| Reset problem | 4 | 1.3% | 0.3% |
| Defibrillation/stimulation problem | 3 | 1% | 1% |
| Capturing problem | 2 | 0.7% | 1.5% |
| Low impedance | 2 | 0.7% | 2.8% |
| Migration or expulsion of device | 2 | 0.7% | 0.3% |
FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.
Patient problems coded
| Patient problem (FDA code) | Reports | Share |
|---|---|---|
| Shock from patient lead(s) | 73 | 24.6% |
| Tachycardiafast heart rate | 14 | 4.7% |
| Bacterial infectiona bacterial infection | 5 | 1.7% |
| Bradycardiaslow heart rate | 5 | 1.7% |
| Dizzinesslight-headedness or unsteadiness | 4 | 1.3% |
| Erosion | 4 | 1.3% |
| Syncope/fainting | 4 | 1.3% |
| Ventricular fibrillationa chaotic rhythm from the lower heart chambers | 4 | 1.3% |
| Arrhythmia | 3 | 1% |
| Bacteremia | 3 | 1% |
| No patient involvement | 3 | 1% |
| Dyspneashortness of breath | 2 | 0.7% |
| Erythemaskin redness | 2 | 0.7% |
| Pocket erosion | 2 | 0.7% |
| Sepsisa severe body-wide response to infection | 2 | 0.7% |
Patient problem codes are present mainly in reports filed since 2019 and are often blank.
In context
| Measure | Visia AF MRI S VR SureScan | Product code LWS | All MAUDE reports |
|---|---|---|---|
| Reports | 297 | 380,959 | 26,136,888 |
| Share of that pool | — | 0.1% | 0% |
| Classified as death, per 1,000 reports | 13 | 27 | 9 |
| Classified as injury | 71.7% | 59.6% | 36.2% |
| Classified as malfunction | 26.9% | 37.4% | 62.3% |
| Filed by the manufacturer | 100% | 97.8% | 94.9% |
Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Other brands with product code LWS
| Brand | Reports | Latest 12 months | Classified as death |
|---|---|---|---|
| Sprint Quattro Secure S MRI SureScan | 36,895 | 6,436 | 1.4% |
| Emblem Mri S-Icd | 21,480 | 3,088 | 0.2% |
| Sprint Quattro Secure | 24,237 | 2 | 5.2% |
| Emblem S-Icd | 17,250 | 2,237 | 0.1% |
| Sprint Fidelis | 17,005 | 340 | 14.1% |
| Sprint Quattro Secure S | 14,398 | 0 | 2.4% |
| Endotak Reliance | 25,897 | 238 | 1.2% |
| Sprint Quattro Secure MRI SureScan | 15,606 | 1,903 | 1.4% |
| Endotak Reliance G | 10,115 | 1,049 | 0.6% |
| Teligen | 16,537 | 47 | 0.6% |
| Durata Sts Optim Active Fixation | 9,681 | 301 | 5.6% |
| Sprint Quattro | 5,591 | 0 | 2.6% |
| Reliance 4-Front | 9,852 | 2,024 | 0.4% |
| Sprint | 6,131 | 161 | 2.4% |
| Vitality 2 | 4,779 | 0 | 1% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."
Questions about Visia AF MRI S VR SureScan reports
How many FDA reports name Visia AF MRI S VR SureScan?
297 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 34 in the latest 12 months.
What kinds of events are reported?
injury (71.7%), malfunction (26.9%) and death (1.3%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.
What device problems are coded?
device sensing problem (34%), inappropriate/inadequate shock/stimulation (24.2%), premature discharge of battery (11.8%), pacing problem (10.8%) and signal artifact/noise (10.4%). These are FDA's device problem codes as entered on the report.
Who files these reports?
manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.
Do these reports show that Visia AF MRI S VR SureScan was at fault?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."
How do I report a problem with a medical device?
Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.